Drug data last refreshed 12h ago · AI intelligence enriched 1mo ago
VENTOLIN is an oral tablet formulation approved in 1986 as a small-molecule NDA by GSK. The specific indication and mechanism of action are not documented in available data. This product represents a legacy asset in GSK's portfolio.
As LOE approaches, the brand team will likely shift focus to defending market share against generics and managing revenue decline, with reduced headcount and investment.
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
A Study Evaluating the Effect of Inhaled PT007(AS MDI) Versus Placebo MDI and Ventolin Evohaler on Lung Function in Adult Participants With Asthma
Green (Sustainable) VENTOLIN - Pharmacokinetics (PK) Study in Healthy Participants
A Study to Assess the Systemic Exposure of FLIXOTIDE™ (Fluticasone Propionate) and SERETIDE™ (Fluticasone Propionate and Salmeterol) Given With VENTOLIN™ Mini-Spacer Compared to the Aerochamber Plus Spacer
A Study to Evaluate the Efficacy and Safety of Meptin® Swinghaler® and Ventolin® MDI in Stable Asthma Patients
Worked on VENTOLIN at GSK? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Zero current job openings linked to VENTOLIN reflects its mature, declining lifecycle stage. Roles on this product typically involve defending legacy revenue and managing generic transition rather than driving growth or innovation.